注册 登录  
 加关注
   显示下一条  |  关闭
温馨提示!由于新浪微博认证机制调整,您的新浪微博帐号绑定已过期,请重新绑定!立即重新绑定新浪微博》  |  关闭

liusongjifan2的博客

读书是同智者交流;读书是对神奇世界的探访;读书是和挚友娓娓谈心 !

 
 
 

日志

 
 

【转载】The Lancet Oncology  

2016-04-28 10:07:38|  分类: 医学知识 |  标签: |举报 |字号 订阅

  下载LOFTER 我的照片书  |
Logo
Weekly Update
April 27, 2016
Weekly Features:
Research | HERACLES trial: trastuzumab and lapatinib in patients with HER2-positive colorectal cancer
Andrea Sartore-Bianchi and colleagues present the results of the HERACLES trial, which assessed the antitumour activity of trastuzumab and lapatinib in patients with HER2-positive colorectal cancer. Their findings suggest that the combination of trastuzumab and lapatinib is active and safe in treatment-refractory patients.
Read this Article →
The Lancet Choice
The Lancet Choice | Access any 5 articles from The Lancet Clinic for a reduced rate
The Lancet Choice gives you the freedom and flexibility to access 5 paywall articles of your choice fromThe Lancet Clinic's ever-growing collection of disease pages - all for the reduced introductory rate of $69.00.
Find out more →
Visit The Lancet Clinic →
Online First:
John Cole/Science Photo Library
NEWS
NHS England misses cancer referral targets again
National Health Service (NHS) England has missed its target to have 85% of patients with cancer start treatment within 62 days of urgent referral from their general practitioner, according to official statistics for February, 2016.
Read this Report →
NEWS
Thyroid cancer subtype downgraded to non-cancer
Encapsulated follicular variant of papillary thyroid carcinoma (EFVPTC) has been reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP), an international panel has announced.
Read this Report →
Colour enhanced x-ray of a patient with colon cancer — Science Photo Library
COMMENT
Targeting HER2: precision oncology for colorectal cancer
Hans-Joachim Schmoll comments on the findings of the HERACLES trial, which assessed the antitumour activity of trastuzumab and lapatinib in patients with HER2-positive colorectal cancer.
Read this Comment →
ARTICLES
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
Andrea Sartore-Bianchi and colleagues present the results of the HERACLES trial, which assessed the antitumour activity of trastuzumab and lapatinib in patients with HER2-positive colorectal cancer. Their findings suggest that the combination of trastuzumab and lapatinib is active and safe in treatment-refractory patients.
Read this Article →
Announcements:
Alerts
Stay Connected
You are receiving our new The Lancet Oncology Weekly Update as an extension to the Table of Contents alert service to which you are subscribed. We hope that you find this weekly roundup of breaking news, comment, and research informative and useful.

If you would prefer not to receive these weekly updates, but wish to continue receiving the monthly Table of Contents alert, please click here:
Unsubscribe from Weekly Updates →

For all the very latest news, comment, and research follow The Lancet Oncology on Twitter.
Follow us →
This email has been sent from The Lancet, Elsevier Limited, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, registered in England with registered number 1982084. 

Copyright ? 2016 Elsevier Limited. All rights reserved. THE LANCET ? is a registered trademark of RELX Intellectual Properties SA, used under license. 

To unsubscribe from The Lancet Oncology Weekly Updates, but continue receiving the monthly Table of Contents alert, please click here →

To unsubscribe from all Table of Contents alerts, please edit your mailing preferences by logging in to your TheLancet.com account: 

Update mailing preferences
【转载】The Lancet Oncology - liusongjifan2 - liusongjifan2的博客 【转载】The Lancet Oncology - liusongjifan2 - liusongjifan2的博客
  评论这张
 
阅读(8)| 评论(0)
推荐 转载

历史上的今天

在LOFTER的更多文章

评论

<#--最新日志,群博日志--> <#--推荐日志--> <#--引用记录--> <#--博主推荐--> <#--随机阅读--> <#--首页推荐--> <#--历史上的今天--> <#--被推荐日志--> <#--上一篇,下一篇--> <#-- 热度 --> <#-- 网易新闻广告 --> <#--右边模块结构--> <#--评论模块结构--> <#--引用模块结构--> <#--博主发起的投票-->
 
 
 
 
 
 
 
 
 
 
 
 
 
 

页脚

网易公司版权所有 ©1997-2017